BPG is committed to discovery and dissemination of knowledge
Basic Study
Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Hepatol. Nov 27, 2026; 18(11): 124302
Published online Nov 27, 2026. doi: 10.4254/wjh.124302
Nanostructured propolis attenuates experimental liver fibrosis and is associated with changes in LC3 and p62 expression
Samar Ramadan Mohammed, Ahmed El-Sayed Nour El Deen, Wael M Elsaed, Eman E Elwakeel, Amiran Osman, Eman S El-Ashry, Rania N Sherif, Kamal G Botros, Sally Abdallah Mostafa, Dina Abdalla Arida
Samar Ramadan Mohammed, Wael M Elsaed, Rania N Sherif, Kamal G Botros, Dina Abdalla Arida, Department of Human Anatomy and Embryology, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt
Ahmed El-Sayed Nour El Deen, Department of Basic Medical and Dental Sciences, Faculty of Dentistry, Zarqa University, Zarqa 13110, Jordan
Ahmed El-Sayed Nour El Deen, Department of Physiology, Faculty of Medicine, Al-Azhar University, Assuit 32811, Egypt
Wael M Elsaed, Preclinical Medical Department, College of Medicine and Dentistry, Riyadh Elm University, Riyadh 12734, Saudi Arabia
Eman E Elwakeel, Department of Basic Sciences, Riyadh Elm University, Riyadh 12734, Saudi Arabia
Amiran Osman, Department of Histology and Cell Biology, Faculty of Medicine, Kafrelsheikh University, Kafr El Sheikh 33516, Egypt
Amiran Osman, Department of Anatomy and Histology, Faculty of Medicine, Mutah University, Karak 61710, Jordan
Eman S El-Ashry, Department of Pharmacology, Faculty of Veterinary Medicine, Mansoura University, Mansoura 35516, Egypt
Sally Abdallah Mostafa, Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt
Co-first authors: Samar Ramadan Mohammed and Ahmed El-Sayed Nour El Deen.
Author contributions: Mohammed SR and Nour El Deen AES contributed equally to this manuscript as co-first authors; Mohammed SR, Nour El Deen AES, Elsaed WM, Elwakeel EE, El-Ashry ES, Sherif RN, Botros KG, Mostafa SA, and Arida DA contributed to conceptualization; Mohammed SR, Nour El Deen AES, Elsaed WM, Elwakeel EE, El-Ashry ES, Botros KG, Mostafa SA, and Arida DA contributed to methodology; Mohammed SR, Osman A, El-Ashry ES, Mostafa SA, and Arida DA contributed to investigation; Mohammed SR, Osman A, Mostafa SA, and Arida DA contributed to formal analysis; Mohammed SR and Elsaed WM contributed to data curation; Mohammed SR, El-Ashry ES, Mostafa SA, and Arida DA contributed to writing - original draft; Nour El Deen AES contributed to validation and funding acquisition; Nour El Deen AES, Elsaed WM, and Mostafa SA contributed to resources; Nour El Deen AES, Elsaed WM, Osman A, Elwakeel EE, Sherif RN, and Botros KG contributed to writing - review and editing; Nour El Deen AES, Sherif RN, and Botros KG contributed to supervision; Osman A, Elwakeel EE, and El-Ashry ES contributed to visualization; Botros KG contributed to project administration. All authors approved final revision of the paper.
AI contribution statement: The authors used AI tools (ChatGPT) solely for language editing and proofreading during manuscript preparation. AI tools were not used to generate, analyze, interpret, or fabricate experimental data, figures, images, statistical analyses, or scientific conclusions. The authors take full responsibility for the content, accuracy, and integrity of the manuscript.
Supported by the Deanship of Scientific Research at Zarqa University.
Institutional animal care and use committee statement: All experimental procedures were approved by the Mansoura University Animal Care and Use Committee (MU-ACUC; approval No. VM.R.25.01.205) and conducted in accordance with the NIH Guide for the Care and Use of Laboratory Animals.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Data sharing statement: The datasets generated and/or analyzed during the current study are available from the corresponding author upon reasonable request.
Corresponding author: Ahmed El-Sayed Nour El Deen, PhD, Professor, Department of Basic Medical and Dental Sciences, Faculty of Dentistry, Zarqa University, 52 Al-Karama Street, New Zarqa, Zarqa 13110, Jordan. a.nourelden@zu.edu.jo
Received: June 12, 2026
Revised: July 3, 2026
Accepted: October 22, 2026
Published online: November 27, 2026
Processing time: 162 Days and 6.4 Hours
Abstract
BACKGROUND

Liver fibrosis is characterized by persistent activation of hepatic stellate cells and excessive extracellular matrix deposition, and effective antifibrotic therapies remain limited.

AIM

To investigate whether nanostructuring enhances the antifibrotic efficacy of propolis against carbon tetrachloride (CCL4)-induced liver fibrosis and examined its association with changes in the autophagy-related markers microtubule-associated protein 1 light chain 3 (LC3) and sequestosome 1 (p62).

METHODS

Male Sprague-Dawley rats were exposed to CCL4 for eight weeks with or without concomitant administration of conventional propolis or propolis nanoparticles. Biochemical, histopathological, oxidative stress, and molecular analyses were performed, including assessment of LC3 and p62 expression at the mRNA and immunohistochemical protein levels.

RESULTS

CCL4 administration induced marked hepatic injury, oxidative stress, and liver fibrosis, accompanied by increased LC3 expression and reduced p62 expression. Both propolis formulations attenuated these alterations; however, propolis nanoparticles produced more pronounced improvements in biochemical, histopathological, oxidative stress, and molecular parameters than conventional propolis and were associated with partial attenuation of the CCL4-induced changes in LC3 and p62 expression.

CONCLUSION

These findings suggest that nanoformulation may improve the antifibrotic efficacy of propolis in experimental liver fibrosis. The observed alterations in LC3 and p62 were associated with the protective effects of propolis nanoparticles; however, because autophagic flux was not directly assessed, these findings should be interpreted as changes in autophagy-related marker expression rather than definitive evidence of altered autophagic activity. Further studies are warranted to clarify the underlying mechanisms and evaluate the translational potential of this approach.

Keywords: Liver fibrosis; Propolis nanoparticles; Autophagy; Carbon tetrachloride; Oxidative stress

Core Tip: This study demonstrates that nanostructured propolis exerts greater antifibrotic effects than conventional propolis in a carbon tetrachloride-induced rat model of liver fibrosis. Propolis nanoparticles significantly reduced liver injury, oxidative stress, and collagen deposition while partially reversing alterations in the autophagy-related markers microtubule-associated protein 1 light chain 3 and sequestosome 1. These findings suggest that nanostructuring enhances the biological activity of propolis and support its potential as a promising strategy for improving antifibrotic therapy.

Write to the Help Desk